0HRT Stock Chart & Stats
$0.02
-$0.01(-33.44%)
At close: 4:00 PM EDT
$0.02
-$0.01(-33.44%)
Day’s Range― - ―
52-Week Range$0.02 - $0.05
Previous CloseN/A
Volume80.00
Average Volume (3M)0.00
Market Cap
$3.90M
Enterprise Value$5.97
Total Cash (Recent Filing)$266.00K
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta-0.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding225,829,130
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Brand Position And Regulatory AccessLeading retail position supports distribution, recognition and repeat demand. Potential CMS reimbursement could broaden access to eligible products and create an additional channel, although execution and adoption will determine the eventual benefit.
Cost Structure And Manufacturing EfficiencyLower overhead and greater manufacturing control can improve gross-profit retention and reduce reliance on external suppliers. If sustained, these changes may support operating leverage and move the business closer to self-funded operations.
Product And Channel DiversificationExpanding beyond cannabinoids reduces dependence on a contracting category and creates more opportunities for product innovation. A substantial direct-to-consumer mix also provides owned customer access, potentially improving data, retention and channel economics.
Bears Say
Persistent Revenue And Unit DeclineSustained top-line and unit contraction indicates that category weakness and demand pressure remain unresolved. Lower volume can dilute fixed-cost absorption, limit investment capacity and make the company’s path to durable profitability more difficult.
Ongoing Losses And Negative Cash GenerationThe company is not yet consistently self-funding despite operational improvements. Continued losses and cash burn could require external financing, constrain product investment and increase vulnerability if revenue recovery or breakeven is delayed.
Liquidity And Regulatory Execution RiskVery limited cash reduces the buffer available for compliance, inventory and growth initiatives. Regulatory changes may also force reformulation or restrict offerings, creating execution costs and further pressure on already declining sales.
CV Sciences News
0HRT FAQ
What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest share price was $0.02 and its highest was $0.05 in the past 12 months.
What is CV Sciences Inc’s market cap?
CV Sciences Inc’s market cap is $3.90M.
When is CV Sciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CV Sciences Inc’s earnings last quarter?
Currently, no data Available
Is CV Sciences Inc overvalued?
According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued.
Does CV Sciences Inc pay dividends?
CV Sciences Inc does not currently pay dividends.
What is CV Sciences Inc’s EPS estimate?
CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences Inc have?
CV Sciences Inc has 225,829,130 shares outstanding.
What happened to CV Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CV Sciences Inc?
Currently, no hedge funds are holding shares in GB:0HRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CV Sciences Inc
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
0HRT Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
cbdMD
―
Cosmos Holdings
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―










